These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35078455)

  • 1. The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    van Eijk M; Vermunt MAC; van Werkhoven E; Wilthagen EA; Huitema ADR; Beijnen JH
    BMC Cancer; 2022 Jan; 22(1):104. PubMed ID: 35078455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel-based versus docetaxel-based regimens in metastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
    Qi WX; Shen Z; Lin F; Sun YJ; Min DL; Tang LN; He AN; Yao Y
    Curr Med Res Opin; 2013 Feb; 29(2):117-25. PubMed ID: 23216340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
    Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel.
    Schröder CP; de Munck L; Westermann AM; Smit WM; Creemers GJ; de Graaf H; Stouthard JM; van Deijk G; Erjavec Z; van Bochove A; Vader W; Willemse PH
    Eur J Cancer; 2011 Jun; 47(9):1355-62. PubMed ID: 21251813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination versus sequential single agent chemotherapy for metastatic breast cancer.
    Dear RF; McGeechan K; Jenkins MC; Barratt A; Tattersall MH; Wilcken N
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):CD008792. PubMed ID: 24347031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials.
    Bria E; Cuppone F; Ciccarese M; Nisticò C; Facciolo F; Milella M; Izzo F; Terzoli E; Cognetti F; Giannarelli D
    Cancer Treat Rev; 2006 Dec; 32(8):583-7. PubMed ID: 16919884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.
    Gradishar WJ; Krasnojon D; Cheporov S; Makhson AN; Manikhas GM; Clawson A; Bhar P
    J Clin Oncol; 2009 Aug; 27(22):3611-9. PubMed ID: 19470941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-weekly docetaxel in treatment of advanced breast cancer: A preliminary study.
    Lee DW; Kang IH; Ismail F
    Med J Malaysia; 2020 Jul; 75(4):338-341. PubMed ID: 32723991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
    Botrel TE; Clark O; Lima Pompeo AC; Horta Bretas FF; Sadi MV; Ferreira U; Borges Dos Reis R
    PLoS One; 2016; 11(6):e0157660. PubMed ID: 27308831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.
    Tabernero J; Climent MA; Lluch A; Albanell J; Vermorken JB; Barnadas A; Antón A; Laurent C; Mayordomo JI; Estaun N; Losa I; Guillem V; Garcia-Conde J; Tisaire JL; Baselga J
    Ann Oncol; 2004 Sep; 15(9):1358-65. PubMed ID: 15319242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis.
    Mauri D; Kamposioras K; Tsali L; Bristianou M; Valachis A; Karathanasi I; Georgiou C; Polyzos NP
    Cancer Treat Rev; 2010 Feb; 36(1):69-74. PubMed ID: 19945225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxane-containing regimens for metastatic breast cancer.
    Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial.
    Nuzzo F; Morabito A; Gravina A; Di Rella F; Landi G; Pacilio C; Labonia V; Rossi E; De Maio E; Piccirillo MC; D'Aiuto G; Thomas R; Rinaldo M; Botti G; Di Bonito M; Di Maio M; Gallo C; Perrone F; de Matteis A
    BMC Cancer; 2011 Feb; 11():75. PubMed ID: 21324184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
    Taylor AM; Chan DLH; Tio M; Patil SM; Traina TA; Robson ME; Khasraw M
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011395. PubMed ID: 33886122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
    Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
    Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial.
    Mey U; Gorschlüter M; Ziske C; Kleinschmidt R; Glasmacher A; Schmidt-Wolf IG
    Anticancer Drugs; 2003 Mar; 14(3):233-8. PubMed ID: 12634618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
    Ford HE; Yap YS; Miles DW; Makris A; Hall M; Miller L; Harries M; Smith IE; Johnston SR
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):809-15. PubMed ID: 16528527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study of nab-paclitaxel as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
    Tamura K; Inoue K; Masuda N; Takao S; Kashiwaba M; Tokuda Y; Iwata H; Yamamoto N; Aogi K; Saeki T; Nakayama T; Sato N; Toyama T; Ishida T; Arioka H; Saito M; Ohno S; Yamauchi H; Yamada K; Watanabe J; Ishiguro H; Fujiwara Y
    Cancer Sci; 2017 May; 108(5):987-994. PubMed ID: 28256066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.
    Rivera E; Mejia JA; Arun BK; Adinin RB; Walters RS; Brewster A; Broglio KR; Yin G; Esmaeli B; Hortobagyi GN; Valero V
    Cancer; 2008 Apr; 112(7):1455-61. PubMed ID: 18300256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.